other material
confidence high
sentiment positive
materiality 0.70
Movano Health raises $24M, reports Q4 operating loss of $6.0M, achieves FDA accuracy milestone
Corvex, Inc.
- Executed $24M private placement including $3.0M from a tier-1 medical device company and $3.6M from insiders.
- Q4 2023 operating loss of $6.0M, improved from $8.0M loss in Q4 2022.
- Second hypoxia trial: Evie Ring pulse oximeter RMSE 2.46% (FDA guideline 3.5%), exceeding two hospital-grade reference devices.
- Ended 2023 with $6.1M cash; new financing extends runway for Evie Med FDA submission and B2B strategy.
- Launched Evie Ring in Nov 2023; revenue recognition begins in 2024 as shipments started Jan 2024.